Literature DB >> 22499090

Predictors of response to immunomodulation in patients with myasthenia gravis.

Hans D Katzberg1, Carolina Barnett, Vera Bril.   

Abstract

INTRODUCTION: Factors determining response to intravenous immunoglobulin (IVIg) and plasmapheresis in myasthenia gravis (MG) have not been evaluated systematically.
METHODS: This study included patients treated with IVIg (n = 63) or plasmapheresis (n = 42) from two trials evaluating IVIg vs. placebo or plasmapheresis in MG. Response was defined as improvement in the quantitative myasthenia gravis score (QMGS) of ≥3.5 points at day 14. Baseline clinical, electrophysiological, and immunological factors were analyzed as predictors.
RESULTS: Baseline QMGS, acetylcholine receptor antibody (AChRAb) positivity, single-fiber electromyography (SFEMG) jitter, and percent abnormal pairs and percent blocking pairs were higher in responders than in non-responders. Using multivariate logistic regression, the odds ratio for response was 13.0 (1.01-381.5) in QMGS 11-17 and 15.3 (1.34-414.3) in QMGS >17 compared with QMGS <11.
CONCLUSIONS: Baseline QMGS, AChRAb positivity, and SFEMG parameters were more abnormal in patients who responded to treatment. Using multivariate regression, baseline QMGS remained as the only significant independent predictor of response.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22499090     DOI: 10.1002/mus.23236

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  3 in total

1.  Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.

Authors:  Rui Zhao; Ying Wang; Xiao Huan; Huahua Zhong; Zhirui Zhou; Jianying Xi; Yuwei Da; Lin Lei; Ting Chang; Zhe Ruan; Lijun Luo; Shengnan Li; Huan Yang; Yi Li; Sushan Luo; Chongbo Zhao
Journal:  J Transl Med       Date:  2021-06-30       Impact factor: 5.531

2.  Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis.

Authors:  Nader Salari; Behnaz Fatahi; Yalda Bartina; Mohsen Kazeminia; Reza Fatahian; Payam Mohammadi; Shamarina Shohaimi; Masoud Mohammadi
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

3.  Factors affecting minimal manifestation status induction in myasthenia gravis.

Authors:  Yi Li; Shumei Yang; Xiaohua Dong; Zhibin Li; Yuyao Peng; Wanlin Jin; Di Chen; Ran Zhou; Fei Jiang; Chengkai Yan; Huan Yang
Journal:  Ther Adv Neurol Disord       Date:  2022-03-29       Impact factor: 6.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.